Date: 2015-09-29
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in The Journal of Clinical and Cellular Immunology
Company: Provectus Pharmaceuticals (USA - TN)
Product: PV-10
Action
mechanism: PV-10 is an investigational new drug containing a proprietary injectable formulation of rose bengal disodium, a water-soluble xanthene dye currently in use in a topical opthalmic diagnostic. PV-10 is designed for injection into solid tumors (intralesional administration).
Disease:
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest
news: * On September 29, 2015, Provectus Biopharmaceuticals reported that the Journal of Clinical and Cellular Immunology has published an article titled, "The Potential of Intralesional Rose Bengal to Stimulate T-Cell Mediated Anti-Tumor Responses. Authors Ajay V Maker, Bellur Prabhakar, and Krunal Pardiwala state that their "article serves to evaluate the potential of intralesional rose bengal [RB] to stimulate T-cell mediated anti-tumor responses in in-vitro, pre-clinical, and clinical studies." The review covers findings in both animal models and human clinical trials covering the use of intralesional RB in the treatment of: melanoma, breast cancer, ovarian cancer, gastric cancer and sarcoma. They conclude, "Our current research is establishing the role of RB in generating anti-tumor immune responses in gastrointestinal cancer and liver metastases. Decrease in tumor burden and stimulation of an immune response with PV-10 has been demonstrated in animal models of metastasis, and correlations of these responses in clinical studies is consistent with such results. That PV-10 treatment can potentially increase circulating cytotoxic T-cells, even in patients who were previously treated with immune-activating checkpoint blockade, supports the possibility that RB induced cytotoxicity may activate T-cells that are responsible for the bystander effect on untreated lesions. As such, intralesional therapy with RB may be a promising new mode of therapy to stimulate T-cell mediated anti-tumor immune responses."
